| Literature DB >> 27744721 |
Lindert Benedictus1,2, Charlotte R Bell3.
Abstract
INTRODUCTION: Bovine neonatal pancytopenia (BNP) is a hemorrhagic disease that emerged in calves across Europe in 2007. Its occurrence is attributed to immunization of the calf's mother with a vaccine produced using an allogeneic cell line. Vaccine-induced alloantibodies specific for major-histocompatibility class I antigens are transferred from the mother to the calf via colostrum, leading to profound depletion of peripheral blood and bone marrow cells that is often fatal. Areas covered: Pubmed and Web of Science were used to search for literature relevant to BNP and the use of allogeneic vaccine cell lines. Following a review of the pathology and pathogenesis of this novel condition, we discuss potential risks associated with the use of allogeneic vaccine cell lines. Expert commentary: Although BNP is associated with a specific vaccine, it highlights safety concerns common to all vaccines produced using allogeneic cell lines. Measures to prevent similar vaccine-induced alloimmune-mediated adverse events in the future are discussed.Entities:
Keywords: Bovine Neonatal Pancytopenia (BNP); Major Histocompatibility Complex class I (MHC I); Vaccine safety; alloantibody; allogeneic; alloimmune; cell line; colostrum; hematopoietic; vaccine production
Mesh:
Substances:
Year: 2016 PMID: 27744721 DOI: 10.1080/14760584.2017.1249859
Source DB: PubMed Journal: Expert Rev Vaccines ISSN: 1476-0584 Impact factor: 5.217